You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

 

Online download statistics by month:

Online download statistics by month: August 2022 to April 2026

AbstractFullPdf
Aug 202214471480397
Sep 2022690703275
Oct 202237638298
Nov 202232832886
Dec 202219719865
Jan 202318218448
Feb 202316316760
Mar 202317417862
Apr 202312512754
May 202312913038
Jun 202314314344
Jul 202310510539
Aug 202313713849
Sep 2023777727
Oct 202325525536
Nov 202313413650
Dec 2023939438
Jan 2024949542
Feb 202412612646
Mar 202411011095
Apr 202412913066
May 202410610736
Jun 202410410351
Jul 2024979747
Aug 2024858537
Sep 202410711130
Oct 202410110129
Nov 2024828334
Dec 202413214749
Jan 2025929249
Feb 202520020061
Mar 202511111159
Apr 2025919239
May 202510310354
Jun 2025686825
Jul 2025110
Aug 2025110
Mar 2026110
Apr 2026110
Total669767902315